OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment

New ex vivo and preclinical data on its first-in-class checkpoint inhibitor OSE-172 targeting selectively SIRP-alpha, a target expressed on myeloid suppressive cells…